We, therefore, suggest that NLOC-015A might represent a new candidate for treating NSCLC via acting as a multi-target inhibitor of EGFR, mTOR, YAP1, and MEK signaling network in NSCLC. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.